Humana Inc.

Humana Inc.

HUM

Get informed when a big investor buys or sells

+ Follow
Market Cap$43.67B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Humana Inc.Humana Inc.34.20.97%7%0.30.8

Earnings Call Q2 2026

July 29, 2026 - AI Summary

2026 performance & near-term outlook (costs, margin, execution): Management said year-to-date performance is “in line with expectations” and remains on track to double individual Medicare Advantage (MA) pretax margin in 2026 (excluding Stars headwind). They guided full-year 2026 medical+pharmacy cost trend to ~7%–8%, noting slight favorability in inpatient. Operationally, the 2Q consolidated operating cost ratio fell 120 bps YoY, with an expectation of ~150 bps full-year improvement—attributed to their transformation/operating model initiatives.
2027 MA bid posture & path to 2028 margin target: Their #1 priority in 2027 bids is margin progression to support a commitment of returning to a sustainable MA pretax margin of at least ~3% in 2028. They expect meaningful progress in 2027, but did not provide bid-specific numeric margin bridge guidance, emphasizing that ultimate results depend on final 2027 membership size/composition. They highlighted that drug trend remains high and is expected to tick modestly higher in 2027, and that they build contingency because bids are set ~6 months ahead and markets can move.
Plan exits (estimated impact) and membership/benefits tradeoffs: For 2027, they expect plan exits impacting ~600,000 members, similar in concept to prior years’ approach, and said they will prioritize higher-performing plans (including those with more value-based care penetration) to reduce disruption and recapture a significant portion of exited members (citing they did so in 2025). They framed this less as a Stars tactic and more as portfolio underwriting margin + capital return optimization.

Exclusive for Stockcircle Pro members

Sign upSign Up
$341.35

Target Price by Analysts

6.1% downsideHumana Target Price DetailsTarget Price
$512.57

Current Fair Value

40.9% upside

Undervalued by 40.9% based on the discounted cash flow analysis.

Share Statistics

Market cap$43.67 Billion
Enterprise Value$51.27 Billion
Dividend Yield$3.54 (0.97%)
Earnings per Share$9.87
Beta0.72
Outstanding Shares120,199,000

Return

Return on Equity6.65%ROE
Return on Assets2.23%
Return on Invested Capital6.59%

Valuation & Multiples

P/E Ratio34.15P/E Ratio
PEG125.76PEG
Price to Sales0.3Price to Sales
Price to Book Ratio2.27Price to Book Ratio
Enterprise Value to Revenue0.35
Enterprise Value to EBIT22.75
Enterprise Value to Net Income40
Total Debt to Enterprise0.28
Debt to Equity0.75Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
July 29, 2026
EPS Estimate
$7.27
Average shareholder expectation
Revenue Estimate
$40.58 B
Average shareholder expectation

Next Earnings Call

Expected Date
November 4, 2026
EPS Estimate
$-0.83
Average shareholder expectation
Revenue Estimate
$40.89 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.0000 88.62%
Total Calls- 100.00%
Total Puts- 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %2.47% 93.31%
Total Invested$1.17B 94.16%
Investors Holding343 492.00%

ESG Score

No data

About Humana Inc.

CEO: Bruce Broussard

Relevant Senate Committees

Finance

This is the most powerful committee for Humana, controlling taxation, trade, and entitlement spending, including the structure and reimbursement rates for Medicare and Medicaid, directly shaping Humana's financial performance and regulatory environment.

Appropriations

This committee allocates federal discretionary spending, directly determining the precise cash flow and funding levels for government healthcare programs (Medicare, Medicaid) that are fundamental to Humana's revenue.

Health, Education, Labor, and Pensions

This committee has direct oversight of health policy, including labor laws which affect home healthcare workers, and overall regulations impacting the healthcare and biotech sectors crucial for Humana.

Special Committee on Aging

Humana's core business heavily serves older Americans through Medicare Advantage and home health. This committee's hearings on drug pricing and long-term care directly create headline risk and influence policy relevant to Humana's operations.

Veterans' Affairs

Humana, as a major healthcare provider and home health service, is directly impacted by VA funding decisions and policies related to veterans' healthcare and benefits.